glp-1 agonists long term side effects The cardiovascular of receptor beyond obesity and type 2 diabetes: An anti-atherosclerotic action Exploring the Side Effects of

Less motivated

L., Morley J

Amylase, lipase, and acute pancreatitis in people with type 2 diabetes treated with liraglutide: results from the LEADER randomized trial

For high burden atherosclerosis, there was an observed attenuation of endothelial dysfunction in the liraglutide treatment group

These results follow similar findings from the companys ATTAIN-1 trial released earlier this month, which tested the drug on people who were overweight or obese without type 2 diabetes (in general, people without diabetes tend to lose more weight from GLP-1 therapy than those with diabetes)

While recognized for its leadership in metabolic health, Pendulum is advancing broader applications of the microbiome to unlock new possibilities in preventive and therapeutic care